Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma

Abedallaa, N.; Tremblay, Lise; Baey, Charlotte; Fabre, Dominique; Planchard, David; Pignon, Jean-Pierre; Guigay, J.; Péchoux, C. Le; Soria, Jean Charles; Montpréville, Vincent Thomas de; Besse, Benjamin

doi:10.1097/jto.0b013e3182572ead

Cited by 23 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, many studies have reported that perioperative chemotherapy may be beneficial in patients with resected LCNEC [32, 36, 37]. Tanaka et al [38] performed a unique study and suggested that perioperative chemotherapy might benefit the survival of patients with LCNEC if the tumors are not immunoreactive to the three neuroendocrine markers evaluated.…”

Section: Surgery For Patients With Lcnecmentioning

confidence: 99%

Treatment options for patients with large cell neuroendocrine carcinoma of the lung

Iyoda

Makino

Koezuka

et al. 2014

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Large cell neuroendocrine carcinoma (LCNEC) of the lung is categorized as a variant of large cell carcinomas, and LCNEC tumors display biological behaviors resembling those of small cell lung carcinomas and features of high-grade neuroendocrine tumors. Because patients with LCNEC have a poor prognosis, surgery alone is not sufficient. Multimodality therapies, including adjuvant chemotherapy, appear promising for improved prognosis in patients with LCNEC. In this review article, we discuss treatment options for patients with LCNEC of the lung.

show abstract

Section: Surgery For Patients With Lcnecmentioning

confidence: 99%

Treatment options for patients with large cell neuroendocrine carcinoma of the lung

Iyoda

Makino

Koezuka

et al. 2014

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…Certain retrospective reviews of LCNEC patients undergoing surgery have indicated that surgical resection tends to improve overall survival. For such resectable patients, it has been demonstrated that perioperative adjuvant chemotherapy favors survival compared with surgery alone (5,(10)(11)(12). With respect to chemotherapeutic agents, the cisplatin-VP-16 doublet regime has been recommended, similar to the recommendation for patients with SCLC.…”

Section: Discussionmentioning

confidence: 99%

“…With respect to chemotherapeutic agents, the cisplatin-VP-16 doublet regime has been recommended, similar to the recommendation for patients with SCLC. This treatment strategy demonstrated satisfactory results in terms of overall survival and recurrence-free survival (11). The majority of previous studies focused on surgically-treated cases due to the difficulty in obtaining a pre-operative pathological diagnosis, therefore, only a small number of studies have evaluated the treatment of advanced LCNEC thus far, including the efficacy of systemic chemotherapy (8,13).…”

Section: Discussionmentioning

confidence: 99%

A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report

Wang

Shen

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study reports the case of an 84-year-old male with primary pulmonary large cell neuroendocrine carcinoma (LCNEC) harboring an epidermal growth factor receptor (EGFR) gene mutation that exhibited a long-lasting response to the EGFR-tyrosine kinase inhibitor (EGFR-TKI) icotinib. The patient had an extensive smoking history, a poor performance status, and presented with an irregular mass in the middle lobe of the right lung on computed tomography (CT) and an enlarged left supraclavicular lymph node on physical examination. Right middle lobe bronchial brushing during fiberoptic bronchoscopy identified poorly-differentiated cancer cells. The left supraclavicular lymph node was biopsied and a diagnosis of metastatic LCNEC was determined. Furthermore, an EGFR exon 19 deletion was identified by DNA sequencing. Following diagnosis, icotinib was administered at a dose of 125 mg three times a day. Chest CT scans were performed after 1 month of treatment, which indicated that the tumor was in partial remission. This marked response to icotinib lasted for 8 months. Thus, the present case illustrates the possibility of identifying EGFR mutations in LCNEC and indicates that EGFR-tyrosine kinase inhibitors may be an alternative treatment strategy for patients with LCNEC harboring activating EGFR mutations.

show abstract

“…Palliation with radiation may play a role in treatment of unresectable disease [3]. According to Abedalla and colleagues, results suggest that perioperative chemotherapy may be beneficial in patients with resected SCLC and LCNEC [46]. …”

Section: Current Treatment and Prognosis Of Neuroendocrine Tumorsmentioning

confidence: 99%

Neuroendocrine Tumors of the Lung

Fisseler‐Eckhoff

Demes

2012

Cancers

View full text Add to dashboard Cite

Neuroendocrine tumors may develop throughout the human body with the majority being found in the gastrointestinal tract and bronchopulmonary system. Neuroendocrine tumors are classified according to the grade of biological aggressiveness (G1–G3) and the extent of differentiation (well-differentiated/poorly-differentiated). The well-differentiated neoplasms comprise typical (G1) and atypical (G2) carcinoids. Large cell neuroendocrine carcinomas as well as small cell carcinomas (G3) are poorly-differentiated. The identification and differentiation of atypical from typical carcinoids or large cell neuroendocrine carcinomas and small cell carcinomas is essential for treatment options and prognosis. Pulmonary neuroendocrine tumors are characterized according to the proportion of necrosis, the mitotic activity, palisading, rosette-like structure, trabecular pattern and organoid nesting. The given information about the histopathological assessment, classification, prognosis, genetic aberration as well as treatment options of pulmonary neuroendocrine tumors are based on own experiences and reviewing the current literature available. Most disagreements among the classification of neuroendocrine tumor entities exist in the identification of typical versus atypical carcinoids, atypical versus large cell neuroendocrine carcinomas and large cell neuroendocrine carcinomas versus small cell carcinomas. Additionally, the classification is restricted in terms of limited specificity of immunohistochemical markers and possible artifacts in small biopsies which can be compressed in cytological specimens. Until now, pulmonary neuroendocrine tumors have been increasing in incidence. As compared to NSCLCs, only little research has been done with respect to new molecular targets as well as improving the classification and differential diagnosis of neuroendocrine tumors of the lung.

show abstract

Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma

Abstract: These results suggest that perioperative chemotherapy may be beneficial in patients with resected SCLC or LCNEC.

Cited by 23 publications

References 36 publications

Treatment options for patients with large cell neuroendocrine carcinoma of the lung

Treatment options for patients with large cell neuroendocrine carcinoma of the lung

A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report

Neuroendocrine Tumors of the Lung

Contact Info

Product

Resources

About